Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naive HIV-1 Subtype C-infected patients in Botswana.
Discussion: Another limitation in this study was the lack of samples with M184V and V106M, making it difficult to draw a conclusion on the performance of PANDAA in detecting V106M and M184V.
Discussion: By using PANDAA, we targeted the most likely mutations to develop to these medications in HIV-1 subtype C, the M184V, K103N and V106M mutations in reverse transcriptase, a targeted and cost-effective approach to genotyping is possible .
Discussion: Common drug resistance mutations associated with resistance to efavirenz include K103N (AAA/G to AAC/T) and V106M .
Transmitted and Acquired HIV-1 Drug Resistance from a Family: A Case Study.
Result: As it turned out, a minor V106M mutation with a frequency of 4.30% was found by NGS platform in patient M but not identified by SBS method.
Result: However, for patient M, V106M alone is associated with a high-level reduction in NVP (60) and EFV (60) susceptibility as well as an intermediate reduction in DOR (50) susceptibility, while together with V106I, especially K101E and K103N, the mutation scores are increased to 65, 135, 25, 150 and 55 for DOR, EFV, ETR, NVP and RPV.
Result: Patient M Acquired K101E, K103N and Minor Mutation of V106M After Improperly Discontinuing Antiretroviral Drugs.
Discussion: As expected, she rapidly acquired K101E,
Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana.
Abstract: The third had K101E in plasma and V106 M in CSF.Our findings suggest that HIV-1 escape and DRM discordance may occur at lower rates in participants with advanced HIV-disease and CM compared to those with HIV associated neurocognitive impairment.
Result: The third participant had HIV-1 strain with RT mutation K101E in plasma and V106 M in CSF.
Discussion: In 1 participant, NNRTI mutations K101E and V106 M were observed in plasma and CSF compartment, respectively.
In vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral-therapy-naive HIV-infected men who have sex with men.
Abstract: Three of the 10 subjects exhibited the presence of major (abundance, >= 20%) viral populations carrying DRM at early/acute stage that later, at the chronic stage, dropped drastically (V106M) or remained highly abundant (E138A).
Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi.
Discussion: Among the 12 patients with K103N and/or V106M mutations (leading to a functional dual NRTI-therapy), only four were alive and on ART at the end of follow-up.
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
PMID: 32925358
2020
Journal of acquired immune deficiency syndromes (1999)
Introduction: Two resistance pathways were identified with DOR in the selection studies in subtype C virus: RT substitution V106A followed by F227I, and V106M followed by F227C.
Introduction: Two resistance pathways were observed with EFV in RT starting with L100I or V106M.
Table: V106M
Discussion: First and foremost, in vitro studies show that, in contrast to V106A or V106M, V106I does not confer a potency reduction to DOR.
Discussion: In this NNRTI-experienced population (N = 6893), intermediate-level (de
Natural presence of the V179D and K103R/V179D mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors in HIV-1 CRF65_cpx strains.
Introduction: The V106M mutation, which confers high-level resistance to efavirenz (EFV) and nevirapine (NVP), is preferentially selected by EFV in subtype C viruses compared with subtype B viruses.
HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance.
Introduction: Patients failing an NNRTI-based first-line regimen with genotypic drug resistance mutations typically present with M184V/I, K65R, and/or thymidine analogue mutations (TAMs) and K103N, V106M/A and/or Y181C as the most prevalent NRTI
Result: The most prevalent NNRTI mutations were K103N (16/36 [44%]) and V106M (9/36 [25%]).
Table: V106M
Discussion: K103N, V106M) drug resistance mutations, typically observed in patients failing an NNRTI-based regimen.
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
PMID: 30769200
2019
International journal of antimicrobial agents
Abstract: High-level DOR resistance was defined as detection of any of Y188L, M230L, G190E, V106A/M+F227L, and V106A/M+L234I.
Abstract: Intermediate DOR resistance was defined as detection of any of V106A/M, Y188C/H, V108I, and K103N+P225H.
Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa.
PMID: 30430843
2019
AIDS research and human retroviruses
Abstract: The most prevalent SDRMs were K103NS (7.5%), M184VI (2.4%), and V106AM (1.4%).
HIV mutation literature information.
PMID: 
2020
AAS open research
Browser Board
Co-occurred Entities
Filtrator
ViMRT